Gynecologic Oncology Articles & Analysis: Older
15 news found
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that preliminary results from the ongoing Phase 1/2 study (NCT04104776) of tulmimetostat (CPI-0209) monotherapy in heavily pretreated patients with advanced cancers showed responses or disease stabilization in five cohorts with evaluable patients. Tulmimetostat is an oral, investigational next-generation selective dual inhibitor of EZH2 and ...
(“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, orally administered progesterone receptor ...
“Onconova’s upcoming Phase 1/2a trial has been thoughtfully designed to explore narazaciclib’s potential as a best-in-class therapy when combined with letrozole in recurrent LGEEC,” said Bhavana Pothuri, MD, Professor, Department of Obstetrics and Gynecology at NYU Grossman School of Medicine and Director, Gynecologic ...
(Nasdaq: LIXT), notes findings by a team of physician-scientists led by principal investigator Dr. Amir Jazaeri, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, and reported at the annual meeting of Society of Gynecologic Oncology (SGO) in Phoenix, AZ, that a ...
(NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will present an analysis based on the June 10th, 2021 data cut from the expansion cohort of the Company’s Phase 1 trial of upifitamab rilsodotin (UpRi) at the upcoming ...
(“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have been selected for poster or symposium presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022, ...
Investigators from the University of Pittsburgh School of Medicine have published a clinical study that demonstrates excellent outcomes for localized intermediate-risk prostate cancer patients treated with Isoray’s Cesium-131 brachytherapy, commercially known as Cesium Blu. The published article on the study, Treatment of intermediate-risk prostate cancer with Cs-131: Long-term results ...
Hard-to-detect cancers like glioblastoma can have survival rates in the single-digit percentages and require elaborate techniques to detect, treat, and monitor. Reveal Surgical is working on changing that reality through its new, AI-based Sentry technology, which leverages a combination of AI and Raman spectroscopy to provide real-time tissue diagnostics during surgery for otherwise-invisible ...
“It is essential that healthcare systems and clinicians continue to invest in innovative and disruptive technology to offer superior healthcare and optimal outcomes for patients,” said Ricardo E. Estape, MD, a practicing gynecology oncologist at Kendall Regional Medical Center and director of HCA Healthcare’s Institute for Gynecologic ...
Company to showcase first and only FDA-authorized surgical robot that features miniature humanoid-shaped arms and host in-booth surgeons to discuss their experiences with Hominis Tel Aviv, Israel and Fort Lauderdale, FL, November 11, 2021 – Memic Innovative Surgery (Memic), a medical device company dedicated to transforming healthcare with its proprietary surgical robotic technology, ...
Introduction Anliprogestins have demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the advancement of this therapeutic class. Onapristone is a full progesterone receptor antagonist originally developed as an oral contraceptive and later evaluated in phase II studies for metastatic breast cancer. Because of liver enzyme elevations ...
Baekelandt is a pioneering expert in gynecological oncology, and endoscopic and robotic surgery. His research focuses on transvaginal natural orifice transluminal endoscopic surgery (vNOTES), of which he has performed over 800 cases. ...
The marker is used prior to high dose rate (HDR) brachytherapy to accurately locate the position of the applicators that guide the placement of radioactive sources for the treatment of multiple cancers, including gynecological cancers. Using the superior imaging properties of MRI, the applicators can be positioned more precisely allowing for more accurate delivery of radiation to ...
” Surgeons from the United States and Europe have used the PlasmaJet in a variety of clinical areas including gynecology, oncology, and plastic surgery. Currently, there are 14 peer-reviewed journal publications on the PlasmaJet covering pre-clinical and clinical studies performed by investigators from multiple specialties. ...
The second annual "Let's Talk... Period" campaign honors and supports September as Ovarian Cancer Awareness Month. Seventh Generation, maker of organic cotton tampons, created "Let's Talk... Period" in support of Ovarian Cancer Research Fund (OCRF), the leading organization dedicated to eradicating ovarian cancer, to provide ovarian cancer education and raise funds to support women fighting the ...